Results 211 to 220 of about 9,966 (258)

A real-world data analysis of Ozanimod in the FDA Adverse Event Reporting System (FAERS) database. [PDF]

Medicine (Baltimore)
Tang Q, Tang X, Hu X, Yin W, Luo L, Li Y, Zhong X.   +6 more
europepmc   +1 more source

Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)

Anna Brameli, Irene Yuan, Elizabeth J. Phillips, Cosby A. Stone   +3 more
openalex   +1 more source

Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system. [PDF]

PLoS One
Kim Y, Yook Y, Rhee SJ.
europepmc   +1 more source

Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Junyi Shen, Rong Hu, Anqi Lin, Aimin Jiang, Bufu Tang, Zaoqu Liu, Quan Cheng, Kai Miao, Jian Zhang, Peng Luo   +9 more
openalex   +1 more source

Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. [PDF]

Thromb J
Zhou J, Wu M, Chen T, Niu P, Zhu Y, Liu Y, Chen H, Zeng X, Zhang J.   +8 more
europepmc   +1 more source

A disproportionality analysis of insulin glargine in the overall population and in pregnant women using the FDA adverse event reporting system (FAERS) database. [PDF]

PLoS One
Liu S, Xu J, Yuan Z, Mei Z, Shi S, Yin J, Deng Y.   +6 more
europepmc   +1 more source

Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023

Yihan Yang, Sheng Wei, Huan Tian, Jing Cheng, Yue Zhong, Xiaoling Zhong, Dunbing Huang, Cai Jiang, Xiaohua Ke   +8 more
openalex   +1 more source

Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System. [PDF]

Front Med (Lausanne)
Tu J, Zhang C, Xie S, He J, Zhang H.
europepmc   +1 more source

Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System. [PDF]

Front Med (Lausanne)
Liu X, Wu F, Li Z, Li C, Li X, Yuan Y, Sun X, Du Y, Du X, Wang S, Xu P.   +10 more
europepmc   +1 more source